FLUCONAZOLE tablet

国家: 美国

语言: 英文

来源: NLM (National Library of Medicine)

有效成分:

FLUCONAZOLE (UNII: 8VZV102JFY) (FLUCONAZOLE - UNII:8VZV102JFY)

可用日期:

St. Mary's Medical Park Pharmacy

INN（国际名称）:

FLUCONAZOLE

组成:

FLUCONAZOLE 150 mg

给药途径:

ORAL

处方类型:

PRESCRIPTION DRUG

疗效迹象:

Fluconazole tablets are indicated for the treatment of: - Vaginal candidiasis (vaginal yeast infections due to Candida ). - Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole tablets were also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. - Cryptococcal meningitis. Before prescribing fluconazole tablets for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole tablets to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: Fluconazole tablets are also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant lab

產品總結:

Fluconazole Tablets USP, 150 mg are light pink to pink colored, may be spotted, modified oval shaped, biconvex, uncoated tablets, debossed with '1139' on one side and plain on the other side and are supplied as follows: NDC 60760-113-01 in unit-dose blister cartons of 1 tablets (1 X 1 Unit-dose) Storage: Store at 20º to 25º C (68º to 77º F) [See USP Controlled Room Temperature]. Manufactured by: Cadila Healthcare Ltd. Baddi, India Distributed by: Zydus Pharmaceuticals (USA) Inc. Pennington, NJ 08534 Rev.: 02/18

授权状态:

Abbreviated New Drug Application

产品特点

FLUCONAZOLE- FLUCONAZOLE TABLET
ST. MARY'S MEDICAL PARK PHARMACY
----------
FLUCONAZOLE TABLETS, USP
RX ONLY
DESCRIPTION
Fluconazole, the first of a new subclass of synthetic triazole
antifungal agents, is available as tablets for
oral administration.
Fluconazole is designated chemically as 2,4-difluoro-α,α
-bis(1H-1,2,4-triazol-1-ylmethyl) benzyl
alcohol with an molecular formula of C
H
F
N
O and molecular weight of 306.3. The structural
formula is:
Fluconazole USP is a white or almost white crystalline powder which is
freely soluble in methanol,
soluble in alcohol and in acetone, sparingly soluble in isopropanol
and in chloroform, slightly soluble
in water, very slightly soluble in toluene..
Each fluconazole tablet, USP intended for oral administration contains
50 mg, 100 mg, 150 mg, or 200
mg of fluconazole USP. In addition, each tablet contains the following
inactive ingredients:
croscarmellose sodium, dibasic calcium phosphate anhydrous, fd&c red
no. 40 aluminum lake,
magnesium stearate, microcrystalline cellulose and povidone.
Fluconazole tablet meets USP Dissolution Test 2.
CLINICAL PHARMACOLOGY
PHARMACOKINETICS AND METABOLISM
The pharmacokinetic properties of fluconazole are similar following
administration by the intravenous
or oral routes. In normal volunteers, the bioavailability of orally
administered fluconazole is over 90%
compared with intravenous administration. Bioequivalence was
established between the 100 mg tablet
and both suspension strengths when administered as a single 200 mg
dose.
1
13
12
2
6
Peak plasma concentrations (C
) in fasted normal volunteers occur between 1 and 2 hours with a
terminal plasma elimination half-life of approximately 30 hours
(range: 20 to 50 hours) after oral
administration.
In fasted normal volunteers, administration of a single oral 400 mg
dose of fluconazole leads to a mean
C
of 6.72 mcg/mL (range: 4.12 to 8.08 mcg/mL) and after single oral
doses of 50 to 400 mg,
fluconazole plasma concentrations and AUC (area under the plasma
concentration-time curve) are dos